IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney patients: drug aims to prevent relapse
Disease control Not yet recruitingThis study tests whether a 15-month course of Nefecon can prevent proteinuria relapse in 288 adults with IgA nephropathy who have already achieved remission. Participants must have completed prior Nefecon therapy and have stable kidney function. The goal is to see if maintenance …
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE4 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug SLN12140 aims to control kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis Phase 2 trial tests SLN12140, an experimental drug, in 48 adults with IgA nephropathy whose disease is not well-controlled by standard treatments. Participants receive different doses of SLN12140 or a placebo for 36 weeks, then all can receive the drug for another year. The …
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Swiss study to track new kidney drug in 50 patients
Disease control Not yet recruitingThis study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key sign of kidney damage. The study is observational, meaning it just watches what happens in real-world use, witho…
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Waid City Hospital, Zurich • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells aim to tame Hard-to-Treat kidney disease
Disease control Not yet recruitingThis early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can herbal granules protect kidneys in IgA disease?
Disease control Not yet recruitingThis study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can reduce protein in the urine of adults with IgA nephropathy, a kidney disease. Researchers will compare the granules to a placebo in 102 participants over several months. The goal is to see if the…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: NA • Sponsor: Keda Lu • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Scientists investigate mysterious loin pain in kidney disease
Knowledge-focused Not yet recruitingThis study looks at what changes occur in the kidneys, urine, and blood when people with IgA nephropathy (IgAN) experience loin pain. Researchers will use MRI scans and lab tests to compare findings during a pain episode and when pain-free. The goal is to better understand the ca…
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: University of Leicester • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New kidney drug trial aims to find safe doses for patients
Knowledge-focused Not yet recruitingThis early-stage study tests a single injection of RG002C0106 in 24 adults to see how kidney function affects the drug's levels and safety. Participants have either normal kidneys or mild-to-moderate kidney impairment. The goal is to gather basic information, not to treat the dis…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE1 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC